Cargando…
Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
OBJECTIVE: To evaluate the pharmacokinetics, safety, and tolerability of brivaracetam (BRV) as 15‐min intravenous (IV) infusion and bolus (≤2‐min injection). METHODS: EP0065 (ClinicalTrials.gov: NCT03405714) was a Phase 2, multicenter, open‐label trial in patients ≥1 month to <16 years of age wit...
Autores principales: | Farkas, Mark Kristof, Kang, Harriet, Fogarasi, Andras, Bozorg, Ali, James, Gareth D., Krauwinkel, Walter, Morita, Diego, Will, Edgar, Elshoff, Jan‐Peer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303197/ https://www.ncbi.nlm.nih.gov/pubmed/35196395 http://dx.doi.org/10.1111/epi.17187 |
Ejemplares similares
-
Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design
por: Bast, Thomas, et al.
Publicado: (2022) -
Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial
por: Farkas, Mark Kristof, et al.
Publicado: (2023) -
Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019) -
Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
por: Schoemaker, Rik, et al.
Publicado: (2017) -
Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015)